Literature DB >> 33578522

Hydronephrosis in patients with cervical cancer is an indicator of poor outcome: A nationwide population-based retrospective cohort study.

You-Rong Yang1, Szu-Ju Chen2, Pin-Yeh Yen1, Chi-Ping Huang1, Lu-Ting Chiu1, Wu-Chou Lin1, Huey-Yi Chen1,3, Yung-Hsiang Chen3,4, Wen-Chi Chen3,4.   

Abstract

ABSTRACT: Cervical cancer is a common malignancy in women. The presence of hydronephrosis in patients with cervical cancer can be a challenging clinical problem. The appropriate management of these patients and the prediction of their outcomes are concerns among gynecologists, urologists, medical oncologists, radiation oncologists, and nephrologists. We enrolled a total of 2225 patients with cervical cancer over a 12-year period from the nationwide database of Taiwan's National Health Insurance Bureau. Among them, 445 patients had concomitant hydronephrosis. The remaining 1780 patients without hydronephrosis were randomly enrolled as a control group for the analysis of associated factors. The results indicated that the proportions of patients with hypertension, chronic kidney disease, and diabetes were significantly higher in the hydronephrosis group. The hydronephrosis group showed a higher all-cause mortality than the non-hydronephrosis group (adjusted hazard ratio 3.05, 95% confidence interval 2.24-4.15, P < .001). The rates of nephrectomy and stone disease were also significantly higher in the hydronephrosis group. A higher percentage of other cancers was also observed in the hydronephrosis group than in the non-hydronephrosis group (12.36% vs 8.99%, respectively). This study shows that cervical cancer with hydronephrosis may have a higher morbidity and mortality than cervical cancer without hydronephrosis. Other factors such as human papilloma virus vaccination, smoking, and cancer staging need to be further studied.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 33578522      PMCID: PMC7886411          DOI: 10.1097/MD.0000000000024182

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  29 in total

1.  Type 2 diabetes and risk of cancer.

Authors:  Ambika Satija; Donna Spiegelman; Edward Giovannucci; Frank B Hu
Journal:  BMJ       Date:  2015-01-02

2.  Hydronephrosis as a prognostic indicator of survival in advanced cervix cancer.

Authors:  Tana S Pradhan; Haiou Duan; Evangelia Katsoulakis; Ghadir Salame; Yi-Chun Lee; Ovadia Abulafia
Journal:  Int J Gynecol Cancer       Date:  2011-08       Impact factor: 3.437

3.  Nephrolithiasis and urinary tract infections: 'the chicken or the egg' dilemma?

Authors:  Loris Borghi; Antonio Nouvenne; Tiziana Meschi
Journal:  Nephrol Dial Transplant       Date:  2012-11       Impact factor: 5.992

4.  Casticin inhibits human prostate cancer DU 145 cell migration and invasion via Ras/Akt/NF-κB signaling pathways.

Authors:  Chia-Chang Lin; Kuen-Bao Chen; Chang-Hai Tsai; Fuu-Jen Tsai; Chih-Yang Huang; Chih-Hsin Tang; Jai-Sing Yang; Yuan-Man Hsu; Shu-Fen Peng; Jing-Gung Chung
Journal:  J Food Biochem       Date:  2019-05-16       Impact factor: 2.720

5.  Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study.

Authors:  Peter G Rose; Shamshad Ali; Charles W Whitney; Rachelle Lanciano; Frederick B Stehman
Journal:  Gynecol Oncol       Date:  2010-02-24       Impact factor: 5.482

6.  Stent-change therapy in advanced malignancies with ureteral obstruction.

Authors:  Bradley H Rosenberg; Fernando J Bianco; David P Wood; Jeffrey A Triest
Journal:  J Endourol       Date:  2005 Jan-Feb       Impact factor: 2.942

7.  Malignant ureteral obstruction: outcomes after intervention. Have things changed?

Authors:  Lih-Ming Wong; Laurence K Cleeve; Alvin D Milner; Alexander G Pitman
Journal:  J Urol       Date:  2007-05-17       Impact factor: 7.450

8.  Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries.

Authors:  J D Boice; N E Day; A Andersen; L A Brinton; R Brown; N W Choi; E A Clarke; M P Coleman; R E Curtis; J T Flannery
Journal:  J Natl Cancer Inst       Date:  1985-05       Impact factor: 13.506

9.  Dietary glycemic index, glycemic load, and cancer risk: results from the EPIC-Italy study.

Authors:  S Sieri; C Agnoli; V Pala; S Grioni; F Brighenti; N Pellegrini; G Masala; D Palli; A Mattiello; S Panico; F Ricceri; F Fasanelli; G Frasca; R Tumino; V Krogh
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

10.  Clinicopathological characteristics and outcomes of metachronous rectal cancer in patients with a history of cervical cancer with and without remote radiotherapy: Reports of 45 cases.

Authors:  Hsinyuan Hung; Jengfu You; Jyming Chiang; Paoshiu Hsieh; Sumfu Chiang; Chengchou Lai; Wensy Tasi; Chienyuh Yeh; Yihjong Chern; Yujen Hsu
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

View more
  1 in total

1.  Intrathoracic ureteric stent migration through a reno-pleural fistula: a case report of rare antegrade ureteric stenting complication.

Authors:  Yi-Hsuan Chen; Marcelo Chen; Yu-Hsin Chen
Journal:  BMC Womens Health       Date:  2021-07-10       Impact factor: 2.809

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.